Arcadia Biosciences(DE:17D)
€3.720.00 (0.00%)
DE:17D
Arcadia Biosciences financials statements
€3.72
At close:0.00 (0.00%)
Arcadia Biosciences (17D) Ratios
0 Followers
Arcadia Biosciences Ratios
DE:17D's free cash flow for Q2 2026 was $-319.00K. For the 2026 fiscal year, DE:17D's free cash flow was increased by $0.00 and operating cash flow was $-319.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.09 | 3.61 | 4.17 | 6.03 | 7.02 |
| Quick Ratio | 2.50 | 3.25 | 3.63 | 5.48 | 6.14 |
| Cash Ratio | 0.13 | 1.66 | 1.82 | 4.90 | 5.69 |
| Solvency Ratio | -0.96 | -0.95 | -1.96 | -1.86 | -1.07 |
| Operating Cash Flow Ratio | -2.30 | -3.76 | -4.26 | -3.32 | -5.13 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 3.95M | $ 1.95M | $ 7.97M | $ 17.38M | $ 22.67M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.05 | 0.07 | 0.08 |
| Debt-to-Equity Ratio | 0.00 | 0.02 | 0.08 | 0.10 | 0.11 |
| Debt-to-Capital Ratio | 0.00 | 0.02 | 0.07 | 0.09 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.58 | 2.17 | 1.53 | 1.38 | 1.41 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1385.60 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1776.30 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.11 | 0.81 | 3.37 | 6.23 |
| Net Debt to EBITDA | 0.11 | 0.55 | 0.96 | 1.26 | 0.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.23% | 41.27% | 51.19% | 17.75% | -28.44% |
| EBIT Margin | -47.98% | -150.88% | -135.11% | -205.28% | -424.12% |
| EBITDA Margin | -47.32% | -148.64% | -128.67% | -198.83% | -408.70% |
| Operating Profit Margin | -205.74% | -72.31% | -137.00% | -188.82% | -523.98% |
| Pretax Profit Margin | -47.98% | -85.41% | -119.47% | -145.78% | -237.94% |
| Net Profit Margin | -48.15% | -139.50% | -313.90% | -207.28% | -216.22% |
| Continuous Operations Profit Margin | -48.15% | -85.57% | -119.65% | -145.97% | -237.96% |
| Net Income Per EBT | 100.34% | 163.33% | 262.75% | 142.19% | 90.88% |
| EBT Per EBIT | 23.32% | 118.12% | 87.20% | 77.20% | 45.41% |
| Return on Assets (ROA) | -35.73% | -52.07% | -70.95% | -53.16% | -33.38% |
| Return on Equity (ROE) | -56.50% | -113.10% | -108.88% | -73.10% | -47.15% |
| Return on Capital Employed (ROCE) | -222.75% | -33.30% | -37.87% | -56.68% | -91.38% |
| Return on Invested Capital (ROIC) | -222.75% | -32.84% | -35.96% | -54.45% | -88.92% |
| Return on Tangible Assets | -35.95% | -52.22% | -71.09% | -53.24% | -33.75% |
| Earnings Yield | -86.35% | -87.20% | -361.12% | -236.65% | -66.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.43 | 4.29 | 8.67 | 6.08 | 4.95 |
| Payables Turnover | 2.13 | 4.21 | 2.71 | 6.74 | 6.17 |
| Inventory Turnover | 2.56 | 3.28 | 1.11 | 2.63 | 1.96 |
| Fixed Asset Turnover | 607.25 | 28.34 | 3.79 | 2.93 | 1.26 |
| Asset Turnover | 0.74 | 0.37 | 0.23 | 0.26 | 0.15 |
| Working Capital Turnover Ratio | 0.89 | 0.56 | 0.27 | 0.29 | 0.24 |
| Cash Conversion Cycle | 3.54 | 109.77 | 236.37 | 144.79 | 200.42 |
| Days of Sales Outstanding | 31.93 | 85.01 | 42.12 | 60.08 | 73.75 |
| Days of Inventory Outstanding | 142.80 | 111.36 | 328.74 | 138.86 | 185.81 |
| Days of Payables Outstanding | 171.19 | 86.60 | 134.48 | 54.14 | 59.14 |
| Operating Cycle | 174.73 | 196.37 | 370.86 | 198.94 | 259.57 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.46 | -7.06 | -12.36 | -23.32 | -48.62 |
| Free Cash Flow Per Share | -3.46 | -7.07 | -12.37 | -23.44 | -50.52 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -601.69 | -3058.80 | -194.13 | -25.69 |
| Capital Expenditure Coverage Ratio | 0.00 | -601.69 | -3058.80 | -194.13 | -25.69 |
| Operating Cash Flow Coverage Ratio | 0.00 | -62.11 | -15.19 | -6.93 | -7.85 |
| Operating Cash Flow to Sales Ratio | -0.98 | -1.91 | -3.43 | -1.88 | -3.82 |
| Free Cash Flow Yield | -174.95% | -119.48% | -395.16% | -216.23% | -121.43% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.16 | -1.15 | -0.28 | -0.42 | -1.51 |
| Price-to-Sales (P/S) Ratio | 0.56 | 1.60 | 0.87 | 0.88 | 3.26 |
| Price-to-Book (P/B) Ratio | 0.65 | 1.30 | 0.30 | 0.31 | 0.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.57 | -0.84 | -0.25 | -0.46 | -0.82 |
| Price-to-Operating Cash Flow Ratio | -0.57 | -0.84 | -0.25 | -0.46 | -0.86 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.02 | 0.00 | 0.03 | -0.06 |
| Enterprise Value Multiple | -1.07 | -0.53 | 0.29 | 0.82 | 0.12 |
| Enterprise Value | 2.45M | 3.98M | -1.64M | -12.13M | -3.26M |
| EV to EBITDA | -1.07 | -0.53 | 0.29 | 0.82 | 0.12 |
| EV to Sales | 0.50 | 0.79 | -0.37 | -1.64 | -0.48 |
| EV to Free Cash Flow | -0.52 | -0.41 | 0.11 | 0.86 | 0.12 |
| EV to Operating Cash Flow | -0.52 | -0.41 | 0.11 | 0.87 | 0.13 |
| Tangible Book Value Per Share | 3.00 | 4.54 | 10.24 | 34.80 | 57.73 |
| Shareholders’ Equity Per Share | 3.03 | 4.56 | 10.38 | 35.09 | 58.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 3.55 | 3.70 | 3.60 | 12.38 | 12.74 |
| Net Income Per Share | -1.71 | -5.16 | -11.30 | -25.65 | -27.56 |
| Tax Burden | 1.00 | 1.63 | 2.63 | 1.42 | 0.91 |
| Interest Burden | 1.00 | 0.57 | 0.88 | 0.71 | 0.56 |
| Research & Development to Revenue | 0.00 | 0.01 | 0.01 | 0.20 | 0.57 |
| SG&A to Revenue | 1.44 | 1.91 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.05 | 0.00 | 0.16 | 0.15 | 0.23 |
| Income Quality | 2.03 | 2.23 | 1.09 | 0.90 | 1.60 |
Currency in USD
